-
Electronic (PDF)
-
CD ROM
-
Hard Copy
-
Site License
-
Enterprisewide
Schizophrenia Therapeutics Market in the US: Market Forecast, Patient Flow, and Competitive Landscape
Commercial Insights, May 2011, Pages: 73
The global schizophrenia therapeutics market was valued at $6.7 billion in 2010, and is expected to reach $7.3 billion by 2018, increasing at a CAGR of 7.5% between 2010 and 2018. The US schizophrenia therapeutics market is expected to increase at a CAGR of 4.5%. The patent expiration of many leading schizophrenia therapies in the US will result in their mass genericization.
However, factors such as rising schizophrenia prevalence, along with an increasing schizophrenia diagnosis rate and schizophrenia treatment rates, will offset the declining market. Also, the report foresees the rapid uptake of Invega Sustenna and some of the high potential pipeline molecules, as significant market events contributing to higher sales revenues.
Research Scope:
- Geographies Covered: The US
- Forecast Period: 8 Years (2010 to 2018)
Market Analysis:
- Schizophrenia therapeutics market size and forecast – Global and the US
- Insights into market events that impact the schizophrenia therapeutics market – The US
- Leading therapies – Global and the US
Competitive Landscape Analysis:
- Market share insights of leading brands – Global and the US
- Future market share analysis of the global schizophrenia therapeutics market
- Profiles of leading brands by annual therapy cost and their market shares
- Market share analysis of the schizophrenia therapeutics market in the US
Patient Flow Analysis:
- Patient flow study with diagnosis rate and treated population rate – Global and the US
- Analysis and forecasts of schizophrenia prevalence population – Global and the US
- Analysis and forecasts of schizophrenia diagnosis population – Global and the US
- Analysis and forecasts of schizophrenia treated population – Global and the US
Unmet Need:
- Unmet need analysis of the global schizophrenia therapeutics market
Pipeline Analysis:
- Analysis of schizophrenia pipeline molecules by phase of development
- Detailed clinical profiles of high potential phase 3 molecules
1 Executive Summary
2 Schizophrenia
2.1 Disease Introduction
2.2 Signs & Symptoms
2.3 Diagnosis
2.4 Treatment
3 Global Schizophrenia Therapeutics Market
3.1 Market Size & Forecast
3.2 Patient Flow Analysis
3.2.1 Epidemiology Analysis
3.2.2 Diagnosis Population Analysis
3.2.3 Treated Population Analysis
4 Geographic Landscape Analysis
5 Current and Future Competition Analysis
5.1 Current Market Share Analysis
5.2 Future Market Share Analysis
5.3 Marketed Therapy Analysis
5.3.1 Seroquel XR
5.3.1.1 Overview
5.3.1.2 Annual Therapy Cost
5.3.1.3 Market Share Analysis
5.3.2 Seroquel
5.3.2.1 Overview
5.3.2.2 Annual Therapy Cost
5.3.2.3 Market Share Analysis
5.3.3 Zyprexa/Zyprexa Zydis/Zyprexa Velotab
5.3.3.1 Overview
5.3.3.2 Annual Therapy Cost
5.3.3.3 Market Share Analysis
5.3.4 Risperdal Consta
5.3.4.1 Overview
5.3.4.2 Annual Therapy Cost
5.3.4.3 Market Share Analysis
5.3.5 Invega
5.3.5.1 Overview
5.3.5.2 Annual Therapy Cost
5.3.5.3 Market Share Analysis
5.3.6 Ablify/Ablify Siscmelt
5.3.6.1 Overview
5.3.6.2 Annual Therapy Cost
5.3.6.3 Market Share Analysis
5.3.7 Geodon/Zeldox
5.3.7.1 Overview
5.3.7.2 Annual Therapy Cost
5.3.7.3 Market Share Analysis
5.3.8 Invega Sustenna
5.3.8.1 Overview
5.3.8.2 Annual Therapy Cost
5.3.8.3 Market Share Analysis
5.3.9 Risperdal/Risperdal M-Tabs
5.3.8.1 Overview
5.3.8.2 Annual Therapy Cost
5.3.8.3 Market Share Analysis
5.3.10 Clozaril/Leponex
5.3.10.1 Overview
5.3.10.2 Annual Therapy Cost
5.3.10.3 Market Share Analysis
5.3.11 Zyprexa Relprew/Zypadhera
5.3.11.1 Overview
5.3.11.2 Annual Therapy Cost
5.3.11.3 Market Share Analysis
6 Schizophrenia Therapeutics Market in the US
6.1 Market Size & Forecast
6.2 Market Events
6.2.1 Market Drivers
6.2.2 Market Restraints
6.3 Competitive Landscape Analysis
6.3.1 Leading Therapies in the US
6.4 Patient Flow Analysis
6.4.1 Epidemiology Analysis
6.4.2 Diagnosis Population Analysis
6.4.3 Treated Population Analysis
14 Unmet Need
15 Schizophrenia Drug Development Pipeline Analysis
15.1 Phase 3 Pipeline Analysis
15.2 Phase 2 Pipeline Analysis
15.3 Phase 1 Pipeline Analysis
15.4 High Potential Therapies
15.4.1 LY-2140023
15.4.1.1 Overview
15.4.1.2 Clinical Studies
15.4.2 Lurasidone
15.4.2.1 Overview
15.4.2.2 Clinical Studies
15.4.3 AZ-004em>
15.4.3.1 Overview
15.4.3.2 Clinicial Studies
15.4.4 RG-1678/RO-4917838
15.4.4.1 Overview
15.4.4.2 Clinical Studies
15.4.5 Cariprazine
15.4.5.1 Overview
15.4.5.2 Clinical Studies
15.4.5 Aripiprazole Depot
15.4.5.1 Overview
15.4.5.2 Clinical Studies
16 Market Participants
17 Appendix
18 Research Methodology
18.1 Overview
18.2 Data Collection
18.2.1 Secondary Data Collection
18.2.2 Primary Data Collection
18.3 Information Objective
18.4 Research Objective
18.4.1 Market Size Estimation & Forecasting
18.4.2 Analysis
18.5 Data Validation
18.6 Contact Us
List of Tables
Table 1: Schizophrenia Therapeutics Market: Market Forecast, Global, 2010-2018
Table 2: Schizophrenia Therapeutics Market: Disease Prevalence, Global, 2010-2018
Table 3: Schizophrenia Therapeutics Market: Diagnosis Population, Global, 2010-2018
Table 4: Schizophrenia Therapeutics Market: Treated Population, Global, 2010-2018
Table 5: Schizophrenia Therapeutics Market: Leading Therapies, Global, 2010
Table 6: Schizophrenia Therapeutics Market: Leading Therapies, The US, 2018
Table 7: Schizophrenia Therapeutics Market: Market Forecasts, The US, 2010-2018
Table 8: Schizophrenia Therapeutics Market: Leading Therapies, The US, 2010
Table 9: Schizophrenia Therapeutics Market: Disease Prevalence, The US, 2010-2018
Table 10: Schizophrenia Therapeutics Market: Diagnosis Population, The US, 2010-2018
Table 11: Schizophrenia Therapeutics Market: Treated Population, The US, 2010-2018
Table 12: Schizophrenia Therapeutics Market: Phase 3 Pipeline Molecules, 2010
Table 13: Schizophrenia Therapeutics Market: Phase 2 Pipeline Molecules, 2010
Table 14: Schizophrenia Therapeutics Market: Phase 1 Pipeline Molecules, 2010
List of Figures
Figure 1: Schizophrenia Therapeutics Market: Market Forecast, Global, 2010-2018
Figure 2: Schizophrenia Therapeutics Market: Patient Flow, Global, 2010
Figure 3: Schizophrenia Therapeutics Market: Disease Prevalence, Global, 2010-2018
Figure 4: Schizophrenia Therapeutics Market: Diagnosis Population, Global, 2010-2018
Figure 5: Schizophrenia Therapeutics Market: Diagnosis Rate, Global, 2010-2018
Figure 6: Schizophrenia Therapeutics Market: Treated Population, Global, 2010-2018
Figure 7: Schizophrenia Therapeutics Market: Treated Population Rate, Global, 2010-2018
Figure 8: Schizophrenia Therapeutics Market: Geographic Landscape Analysis, 2010
Figure 9: Schizophrenia Therapeutics Market: Geographic Landscape Analysis, 2018
Figure 10: Schizophrenia Therapeutics Market: Market Share, Global, 2010
Figure 11: Schizophrenia Therapeutics Market: Market Share, Global, 2010
Figure 12: Schizophrenia Therapeutics Market: Market Forecast, The US, 2010-2018
Figure 13: Schizophrenia Therapeutics Market: Patient Flow, The US, 2010
Figure 14: Schizophrenia Therapeutics Market: Disease Prevalence, The US, 2010-2018
Figure 15: Schizophrenia Therapeutics Market: Diagnosis Population, The US, 2010-2018
Figure 16: Schizophrenia Therapeutics Market: Diagnosis Rate, The US, 2010-2018
Figure 17: Schizophrenia Therapeutics Market: Treated Population, The US, 2010-2018
Figure 18: Schizophrenia Therapeutics Market: Treated Population Rate, The US, 2010-2018
Figure 19: Schizophrenia Therapeutics Market: Drug Pipeline by Clinical Trial Phase, Global, 2010
- Abbott Laboratories
- Abbott Laboratories
- ACADIA Pharmaceuticals Inc.
- Alexza Pharmaceuticals Inc.
- Allon Therapeutics Inc.
- Amgen Inc.
- Aryx Therapeutics
- Astellas
- Astellas Pharma Inc.
- AstraZeneca PLC
- Avineuro Pharmaceuticals Inc.
- Bayside Health
- BioLineRx Ltd.
- Bristol-Myers Squibb
- Cephalon Inc.
- CoMentis Inc.
- Cyrenaic Pharmaceuticals Inc.
- Dainippon Sumitomo Pharma Co. Ltd.
- Eli Lilly and Company
- EnVivo Pharmaceuticals
- EPIX Pharmaceuticals Inc. (Inactive)
- Fabre-Kramer Pharmaceuticals Inc.
- Gedeon Richter Plc.
- GlaxoSmithKline
- GlaxoSmithKline plc
- GlaxoSmithKline plc
- H. Lundbeck A/S
- Hoffmann-La Roche Inc.
- Intra-Cellular Therapies Inc.
- Janseen
- Johnson & Johnson
- Lexicon Pharmaceuticals Inc.
- Merck & Co. Inc.
- Mitsubishi Tanabe Pharma Corporation
- NeuroSearch A/S
- Novartis AG
- NPS Pharmaceuticals Inc.
- Orion Corporation
- Ortho-McNeil-Janssen Pharmaceuticals Inc.
- Otsuka Pharmaceutical Co. Ltd.
- Pfizer Inc.
- Pfizer Inc.
- Potomac Pharma LLC
- Shire Pharmaceutical
- Synosia Therapeutics AG
- Targacept Inc.
- Xytis Inc.
Products Mentioned:
- Ablify
- Ablify Discmelt
- ABT-107
- ABT-126
- ABT-288
- ACR343
- ADX71149
- AL-108
- Alpha 2C Receptor Antagonist
- Amantadine
- AMG 747
- AQW051
- Aripiprazole depot
- Ariprazole oral
- ASP2905
- ATI-9242
- AVN-211
- AZ-004
- AZD3480
- AZD8529
- BF2.649
- BL-1020
- Cannabidiol
- Cannabidiol + Sitagliptin + Intranasal Insulin
- cariprazine
- Cariprazine {(Japan)}
- Cariprazine {(US)
- Ceftriaxone
- CEP-26401
- Clozapine
- Clozaril
- Creatine
- CX516 (Ampakine) + Clozapine Olanzapine or Risperidone
- D-Amino Acid Oxidase (DAAO) Inhibitor
- D-serine
- D-serine + Olanzapine
- Dimethoxybenzylidene anabaseine
- Estradiol
- EU))
- EVP-6124
- Gabitril (tiagabine)
- Galantamine
- Galantamine
- Galantamine hydrobromide (extended release)
- Geodon
- Glycine
- Glycine reuptake inhibitors
- GSK 1144814
- GSK1034702
- GSK239512
- GTS-21
- Intravenous immunoglobulin
- Invega
- Invega sustenna
- ITI-007
- JNJ-37822681
- Ketamine + Nicotine
- L-830982
- Lamotrigine
- Leponex
- Lu 31-130
- Lu AE58054
- Lurasidone
- Lurasidone* (US)
- LX6171
- LY2140023
- Memantine
- Minocycline
- MK-0249
- MK-0777
- MK-5757
- MK-8998
- MK0557
- Modafinil
- MS14 + Risperidone
- Olanzapine + haloperidol + lorazepam
- Olanzapine oral
- Ondansetron
- OPC-34712 ((US
- Oxcarbazepine
- Oxytocin
- Oxytocin
- P-101
- Paliperidone oral
- Paliperidone palmitate
- Paliperidone palmitate (oral extended release) Adolescent Schizophrenia
- PF-217830
- PF-3463275
- PF-5212365
- Phase II (Japan)}
- Pimavanserin + Risperidone
- Pregnenolone
- Pregnenolone
- PRX-07034
- Quetiapine IR
- Quetiapine XR
- R209130
- RG1678
- RG3487
- Risperdal Consta
- Risperdal Consta
- Risperdal M-tabs
- Risperidone depot
- Risperidone oral
- Sarcosine
- Serdolect (US)
- Seroquel
- Seroquel XR
- SPD489
- Sycrest (EU)
- SYN-120
- Targretin (bexatolene)
- TC - 5619
- TC-5619
- TGOFO2N
- THC + Iomazenil
- Tropisetron + Risperidone
- Valacyclovir + Antipsychotic Drug
- Varenicline
- XY4083
- Zeldox
- Zisprasidone oral
- Zyprexa
- Zyprexa Velotab
- Zyprexa Zydis
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
